Clinical Trials Browser

Phase 2 × ALT-803 × Clear all

NCT04847466 2026-04-08

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Phase 2 Active not recruiting

Neoplasms

NCT06161545 2026-04-08

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, B-Cell

NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT07355205 2026-01-21

FLINN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02782546 2025-12-24

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06710288 2025-10-20

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Phase 2 Recruiting

Platinum-resistant Ovarian Cancer

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06765954 2025-05-06

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06765902 2025-05-04

Immunotherapy Before and After Surgery

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04491955 2025-04-24

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Phase 2 Completed

32 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03853317 2024-08-09

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Phase 2 Terminated

9 enrolled 13 charts

Carcinoma, Merkel Cell

NCT02465957 2024-05-02

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Merkel Cell

NCT05445882 2024-04-02

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Castration Resistant Prostate Cancer

NCT02989844 2023-11-03

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Phase 2 Completed

20 enrolled 17 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03050216 2023-07-18

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

Phase 2 Completed

8 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03003728 2020-07-10

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Phase 2 Withdrawn

Multiple Myeloma